Hanusch-Krankenhaus Wiener Gebietskrankenkasse

Vienna 1140

0 studies enrolling now · 4 studies all time

What they study most

HNSCC, HRAS Gene Mutation, Immune Thrombocytopenic Purpura, Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Studies at this site

• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — Stopped early
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early
• Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy — Completed
• Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) — Completed